Sonoma Pharmaceuticals Announces Fiscal First Quarter 2018 Financial Results and Conference Call Jul 25, 2017
CORRECTING and REPLACING -- Sonoma Pharmaceuticals Announces Record Quarterly Prescription Data Jul 13, 2017
Sonoma Pharmaceuticals Announces Publication of Consensus Report Describing Celacyn's (Hypochlorous Acid) Impact on Post-Procedure Treatment and Scar Prevention Jun 28, 2017
Sonoma Pharmaceuticals Announces Two Singapore Approvals for Microcyn® (hypochlorous acid) for the Treatment of Atopic Dermatitis and Hypertrophic / Keloid Scars Jun 20, 2017
Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2017 Financial Results and Conference Call Jun 2, 2017
Sonoma Pharmaceuticals Receives Two New United Arab Emirates Regulatory Approvals: Pediacyn® for Atopic Dermatitis and Epicyn® for Scar Management Apr 12, 2017
Sonoma Pharmaceuticals Receives U.S. FDA Clearance of Loyon® Skin Descaler for Relief of Scaling Associated with Various Dermatoses Mar 29, 2017
Sonoma Pharmaceuticals Receives Final $1.5 Million Payment From Sale of Latin America Business to Invekra S.A.P.I. de C.V. Mar 23, 2017
